Samih Lutfi Samih Khauli, MBBS Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 |
Melisa R Chang, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 |
Dr. Michael Jonathan Lieber, M.D. Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2001 Santa Monica Blvd, Ste 1190w, Santa Monica, CA 90404 Phone: 310-453-1414 Fax: 310-362-8775 |
Dr. Hossein Babaali, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2428 Santa Monica Blvd Ste 402, Santa Monica, CA 90404 Phone: 310-449-4595 Fax: 310-828-6635 |
Yuqing Alexandria Gao, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 |
Dr. Swetha Gogineni, M.D. Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 |
News Archive
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the third quarter of 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended October 3, 2009.
Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed active enrollment of subjects in its U.S.-based PIONEER Pivotal Study of Imagio.
Rhode Island has become the first state to pass a law explicitly requiring coverage for fertility preservation prior to gonadotoxic medical therapy, treatment that could directly or indirectly cause infertility.
Chairman and CEO Patrick K. Donnelly today announced the official launch of Aptiv Solutions, a global biopharmaceutical and medical device development services company.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 1 days ago